Tags

Type your tag names separated by a space and hit enter

Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.
AAPS PharmSciTech. 2020 05 19; 21(5):144.AP

Abstract

Several typos occurred during the production process and captions were misplaced. The corrected captions for Picture 1, Fig. 6-9 are below.

Authors+Show Affiliations

Department of Pharmaceutical Technology, Faculty of Pharmacy Gazi University, Ankara, Turkey. Zoleant Pharmaceuticals International, Istanbul, Turkey.Department of Pharmaceutical Technology, Faculty of Pharmacy Gazi University, Ankara, Turkey.Department of Pharmaceutical Technology, Faculty of Pharmacy Gazi University, Ankara, Turkey. ncelebi51@gmail.com.

Pub Type(s)

Journal Article
Published Erratum

Language

eng

PubMed ID

32430673

Citation

Tashan, Emine, et al. "Correction To: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization By Using Design of Experiment and in Vitro Evaluation." AAPS PharmSciTech, vol. 21, no. 5, 2020, p. 144.
Tashan E, Karakucuk A, Celebi N. Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation. AAPS PharmSciTech. 2020;21(5):144.
Tashan, E., Karakucuk, A., & Celebi, N. (2020). Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation. AAPS PharmSciTech, 21(5), 144. https://doi.org/10.1208/s12249-020-01703-2
Tashan E, Karakucuk A, Celebi N. Correction To: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization By Using Design of Experiment and in Vitro Evaluation. AAPS PharmSciTech. 2020 05 19;21(5):144. PubMed PMID: 32430673.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Correction to: Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation. AU - Tashan,Emine, AU - Karakucuk,Alptug, AU - Celebi,Nevin, Y1 - 2020/05/19/ PY - 2020/5/21/entrez PY - 2020/5/21/pubmed PY - 2020/5/21/medline SP - 144 EP - 144 JF - AAPS PharmSciTech JO - AAPS PharmSciTech VL - 21 IS - 5 N2 - Several typos occurred during the production process and captions were misplaced. The corrected captions for Picture 1, Fig. 6-9 are below. SN - 1530-9932 UR - https://www.unboundmedicine.com/medline/citation/32430673/Correction_to:_Development_of_Nanocrystal_Ziprasidone_Orally_Disintegrating_Tablets:_Optimization_by_Using_Design_of_Experiment_and_In_Vitro_Evaluation L2 - https://dx.doi.org/10.1208/s12249-020-01703-2 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.